重组人类促红细胞生成素防治极低出生体重儿贫血的临床研究

目的 :评价国产重组人类促红细胞生成素 (rh EPO)防治极低出生体重儿 (VLBW)贫血的效果和安全性。方法 :30例 VL BW随机分为治疗组及对照组各 1 5例。治疗组用国产 rh EPO750 IU· kg-1·周 -1 ,每周分 3次皮下注射 ,共 6周 ;对照组未用 rh EPO治疗。两组 VLBW同时补充铁剂 ,根据输血指征必要时予红细胞输注。观察两组 VLBW的血液学参数、输血率及输血量、热卡摄入、体重增长等指标。结果 :治疗组用药后血清促红细胞生成素 (EPO)极显著高于对照组 (P<0 .0 1 ) ;治疗组血红蛋白 (Hb)、红细胞压积 (Hct)、网织红细胞 (Ret)均极显著高于对照组 (P<0 0 1 ) ;治疗组的输血率较对照组明显减少 (P<0 .0 5) ;血清铁蛋白 (SF)水平在用药后治疗组极明显低于对照组 (P<0 .0 0 1 )。观察期间 ,治疗组的体重增长指标较对照组高 (P<0 .0 5)。结论 :国产 rh EPO能有效提高 VLBW的 Hb、 Hct、 Ret,减轻VLBW贫血 ,且用药安全 ,无明显副作用

Clinical Study of Recombinant Human Erythropoietin in Preventing and Treating Anemia of Prematurity in Very Low Birth Weight Infants

Objective:To evaluate clinical efficacy and safety of domestic recombinant human erythropoietin (rhEPO) in preventing and treating anemia of pematurity in very low birth weight (VLBW) infants.Methods:Thirty VLBW infants were randomly divided into rhEPO treated group or control group.RhEPO treated group were given domestic rhEPO subcutaneously from one week of life.Control group received no rhEPO.All infants received oral iron or,if necessary,erythrocytes transfusion.Hematologic parameters,transfusion requirements,caloric intake,and growth were monitored.Results:Serum rhEPO levels of treatment group were significantly higher than those in control grop ( P <0.01).Higher levels of hemoglobin (Hb),hematocrit (Hct) and reticulocyte counts (Ret) were found in rhEPO treated group ( P <0.01).Serum ferritin (SF) level was significantly lower in rhEPO treated group compared with control group ( P <0.001).The frequency of transfusions was lower in rhEPO treated group ( P <0.05).The rhEPO treated infants had a greater weihgt gain during therapy ( P <0.05).Conclusion:Domestic rhEPO therapy can effectively elevate the Hb?Hct?Ret level and is safe and efficient in preventing or treating anemia in VLBW infants.No side effect is found relative to rhEPO.